Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Combinations in Recurrent Glioblastoma
NCT03707457Phase 1Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MK-4166, epacadostat and ipilimumab in glioblastoma (GBM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Mar 2019; status: terminated.
02
Drugs
MK-4166epacadostatipilimumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03707457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707457.